Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer? The following represents disclosure ...

One of the notable candidates in this field is BL-B01D1, developed by Systimmune. This EGFRxHER3 bispecific ADC employs a cleavable linker to connect a novel topoisomerase I (TOP-I) inhibitor payload.

BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success rate ...

BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase I drugs for Metastatic Ovarian Cancer have a 77% phase ...

I am so proud of the accomplishment at SystImmune. Two new #ADCs, M11D01 and M7D01, received IND clearance from the U.S. FDA. Thankful for the hard work by the #SystImmune team!

*GAAP and Non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income. **See "Use of Non-GAAP Financial Information". U.S. revenues increased 9% to $8.6 ...